Education
About Us
Working with TipRanks
Follow Us
NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 45.56M | $ 14.09M | $ 102.69M | $ 0.00 | $ 0.00 |
| Gross Profit | $ 45.56M | $ 14.09M | $ 102.69M | $ 0.00 | $ 0.00 |
| Operating Income | $ -176.29M | $ -182.97M | $ -3.56M | $ -34.98M | $ -6.63M |
| EBITDA | $ -241.49M | $ -176.86M | $ -22.34M | $ -41.37M | $ -6.63M |
| Net Income | $ -241.60M | $ -176.94M | $ -22.63M | $ -41.78M | $ -7.02M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 834.19M | $ 340.45M | $ 467.73M | $ 60.38M | $ 1.37M |
| Total Assets | $ 864.62M | $ 347.10M | $ 478.50M | $ 67.99M | $ 139.87M |
| Total Debt | $ 448.00K | $ 60.00K | $ 126.00K | $ 186.51K | $ 0.00 |
| Net Debt | $ -771.29M | $ -340.39M | $ -467.60M | $ -60.19M | $ -1.37M |
| Total Liabilities | $ 107.12M | $ 58.70M | $ 48.43M | $ 11.36M | $ 12.41M |
| Stockholders' Equity | $ 757.50M | $ 288.39M | $ 430.07M | $ 56.63M | $ 127.46M |
| Cash Flow | |||||
| Free Cash Flow | $ -159.24M | $ -141.24M | $ 10.44M | $ -29.54M | - |
| Operating Cash Flow | $ -158.56M | $ -141.22M | $ 10.66M | $ -29.51M | - |
| Investing Cash Flow | $ -62.85M | $ -24.00K | $ -221.00K | $ -24.00K | - |
| Financing Cash Flow | $ 659.51M | $ 8.91M | $ 391.90M | $ 84.70M | $ 13.92M |